Evaluation De La Cardiotoxicité Du Protocole «FEC» Dans Le Cancer Du Sein Par Dosage De La Troponine Dans Le CAC -Sétif

Abstract

The therapeutic management of breast cancer involves chemotherapy, among the protocols most often used is the FEC protocol. Despite the therapeutic efficacy, the latter causes complications. Cardiotoxicity is one of the most feared that can appear after treatment. Our objective is to evaluate the early cardiotoxic effect of the FEC protocol in patients treated for breast cancer via the ultra-sensitive troponin I assay. To this end, we followed 16 patients during the period from January 2020 until May 2020, at the Center Anti-Cancer of Sétif. The mini-Vidas automat makes it possible to assay troponin I us with a detection limit of 1.5 ng/l. According to our results, the cTnI was negative in all our patients before the start of the treatment, just after the 3rd course the TnI us rose for 8 patients (50%) among them only one patient (6.25%) had troponin greater than the MI cutoff (19 ng/l), 3 weeks after treatment, an increase in TnI us was noted for 10 patients (62.5%) ; the LVEF has been slightly reduced but without exceeding the standards. Despite the low number of patients followed in our study, an increase in us cTnI was recorded. These results confirm the cardiotoxicity induced by this protocol, join the literature and agree with previous studies with somewhat high values. The values found show subclinical cardiac lesions which thus require strict monitoring by cardiologists and subsequent studies to develop cardio-oncology.